Evidence map›Paper›PMID 39653800›Full record

ReviewNature protocols2025

An explainable deep learning platform for molecular discovery.

Felix Wong, Satotaka Omori, Alicia Li, Aarti Krishnan, Ryan S Lach, Joseph Rufo, Maxwell Z Wilson, James J Collins

Abstract readReview
In one paragraph

Review in Nature protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Felix WongInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Satotaka OmoriInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Alicia LiIntegrated Biosciences, Inc., Redwood City, CA, USA.
Aarti KrishnanInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7936-4442
Ryan S LachIntegrated Biosciences, Inc., Redwood City, CA, USA.
Joseph RufoCenter for BioEngineering, University of California Santa Barbara, Santa Barbara, CA, USA.
Maxwell Z WilsonIntegrated Biosciences, Inc., Redwood City, CA, USA.
James J CollinsInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. jimjc@mit.edu.ORCID 0000-0002-5560-8246

Funding

Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosisR01AI146194 · NIAID · UNIVERSITY OF WASHINGTON · PI ALLAND, DAVID, SHERMAN, DAVID R · 2020 to 2024
$4.1M
Physical Biology and Deep Learning for Antibiotic Resistance and DiscoveryK25AI168451 · NIAID · BROAD INSTITUTE, INC. · PI Felix Wong · 2023 to 2026
$486k
NIAID NIH HHS K25 AI168451NIAID NIH HHS R01 AI146194Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) SNSF_ 203071United States Department of Defense | Defense Threat Reduction Agency (DTRA) HDTRA12210032, HDTRA12210010U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-AI146194U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) K25AI168451
6 · The paper itself

Abstract

Deep learning approaches have been increasingly applied to the discovery of novel chemical compounds. These predictive approaches can accurately model compounds and increase true discovery rates, but they are typically black box in nature and do not generate specific chemical insights. Explainable deep learning aims to 'open up' the black box by providing generalizable and human-understandable reasoning for model predictions. These explanations can augment molecular discovery by identifying structural classes of compounds with desired activity in lieu of lone compounds. Additionally, these explanations can guide hypothesis generation and make searching large chemical spaces more efficient. Here we present an explainable deep learning platform that enables vast chemical spaces to be mined and the chemical substructures underlying predicted activity to be identified. The platform relies on Chemprop, a software package implementing graph neural networks as a deep learning model architecture. In contrast to similar approaches, graph neural networks have been shown to be state of the art for molecular property prediction. Focusing on discovering structural classes of antibiotics, this protocol provides guidelines for experimental data generation, model implementation and model explainability and evaluation. This protocol does not require coding proficiency or specialized hardware, and it can be executed in as little as 1-2 weeks, starting from data generation and ending in the testing of model predictions. The platform can be broadly applied to discover structural classes of other small molecules, including anticancer, antiviral and senolytic drugs, as well as to discover structural classes of inorganic molecules with desired physical and chemical properties.

Indexed as

Deep LearningDrug DiscoveryAnti-Bacterial AgentsHumansNeural Networks, ComputerSoftwareAnti-Bacterial Agents

Identifiers

PMID39653800
PMCPMC12668791

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.